Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 6/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 6/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28560 | 1.00 | SLC1A3 (0.51) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| SCHEMBL8824879 | 1.00 | SLC1A3 (0.51) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| SCHEMBL8824882 | 1.00 | SLC1A3 (0.51) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| SCHEMBL28559 | 1.00 | SLC1A3 (0.51) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| Hydrochloric Acid SCHEMBL7049998 | 0.98 | SLC1A3 (0.50) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| Homoserine SCHEMBL28894150 | 0.91 | NOS1 (0.45) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| SCHEMBL12610414 | 0.91 | SLC1A3 (0.44) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| SCHEMBL12610410 | 0.91 | SLC1A3 (0.44) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| Sarcosine SCHEMBL16540746 | 0.89 | SLC1A3 (0.43) | SLC1A3GRIA4GRIA1GRIA3GRIA2 | |
| Sarcosine SCHEMBL16540745 | 0.89 | SLC1A3 (0.43) | SLC1A3GRIA4GRIA1GRIA3GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070294-A | Stable vitreous material based on histidine, arginine and glutamic acid amino acids | 阵序补丁有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025032025-A1 | STABLE GLASSY MATERIAL BASED ON HISTIDINE, ARGININE AND GLUTAMIC ACID AMINO ACIDS | VITROPEP (FR) | 2025-02-13 | — | — | WO | disclosed |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-3981784-A1 | REGULATORS OF CELL DIVISION | Technische Universität Dresden (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-8921306-B2 | Nociceptin mimetics | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-12-30 | — | — | US | disclosed |
| US-20130157928-A1 | NOCICEPTIN MIMETICS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-06-20 | — | — | US | disclosed |
| EP-2576598-A1 | NOCICEPTIN MIMETICS | The University of Queensland (AU) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153583-A1 | NOCICEPTIN MIMETICS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-15 | — | — | WO | disclosed |
| EP-1737884-A4 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | UNIV QUEENSLAND (AU) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008077194-A1 | RECEPTOR AGONISTS | XENOME LTD (AU) | 2008-07-03 | — | — | WO | disclosed |
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| EP-1737884-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | The University of Queensland (AU) | 2007-01-03 | — | — | EP | disclosed |
| EP-1402021-A4 | A GENE AND USES THEREFOR | AUTOGEN RES PTY LTD (AU) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005090388-A1 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-09-29 | — | — | WO | disclosed |
| EP-1402021-A1 | A GENE AND USES THEREFOR | Autogen Research Pty. Ltd. (AU) | 2004-03-31 | — | — | EP | disclosed |
| US-20030216441-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-11-20 | — | — | US | disclosed |
| WO-2002095020-A1 | A GENE AND USES THEREFOR | AUTOGEN RESEARCH PTY LTD (AU) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157928-A1 | NOCICEPTIN MIMETICS | OPRL1, OGFRL1, OPRK1 | SLC1A3 671/4885GRIA4 87/4885GRIA1 40/4885 |
| US-20030216441-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | SLC1A3 4388/4885GRIA4 4508/4885GRIA1 3283/4885 |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | PCNA, BOD1L1, MKI67 | SLC1A3 4406/4885GRIA4 4672/4885GRIA1 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.